Egyesült Államok - angol - NLM (National Library of Medicine)

deseret biologicals, inc - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cysteine (unii: k848jz4886) (cysteine - unii:k848jz4886), manganese gluconate (unii: 9yy2f980sv) (manganese cation (2+) - unii:h6ep7w5457), oxogluric acid (unii: 8id597z82x) (.alpha.-ketoglutaric acid - unii:8id597z82x), fumaric acid (unii: 88xhz13131) (fumaric acid - unii:88xhz13131), germanium sesquioxide (unii: 96we91n25t) (germanium sesquioxide - unii:96we91n25t), iodine (unii: 9679tc07x4) (iodine - unii:9679tc07x4), magnesium (u - ascorbic acid 6 [hp_x] in 1 ml - for the temporary relief of symptoms related to headache, joint pain, sweating, congestion, and fatigue.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to headache, joint pain, sweating, congestion, and fatigue.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

Egyesült Államok - angol - NLM (National Library of Medicine)

mcguff pharmaceuticals, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - ascorbic acid 500 mg in 1 ml - ascor is vitamin c indicated for the short term (up to 1 week) treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. limitations of use ascor is not indicated for treatment of vitamin c deficiency that is not associated with signs and symptoms of scurvy. none. use in specific populations 8.1 pregnancy 8.2 lactation 8.4 pediatric use 8.5 geriatric use 8.6 renal impairment 8.1 pregnancy risk summary there are no available data on use of ascor in pregnant women to inform a drug-associated risk of adverse developmental outcomes; however, use of ascorbic acid (vitamin c) has been used during pregnancy for several decades and no adverse developmental outcomes are reported in the published literature [see data]. there are dose adjustments for ascorbic acid (vitamin c) use during pregnancy [ see clinical considerations ]. animal reproduction studies have not been conducted with ascor. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations dose adjustments during pregnancy and post-partum period follow the u.s. recommended dietary allowances (rda) for pregnant women when considering use of ascor for treatment of scurvy [ see dosage and administration (2.3 )]. data human data there are no available data on use of ascor or another ascorbic acid injection in pregnant women. however, a published meta–analysis of randomized studies evaluating a large number of pregnant women who took oral ascorbic acid (vitamin c) (through diet and supplementation) at doses ranging from 500 to1000 mg/day (2.5 to 5 times the recommended daily intravenous dose, respectively) [ see dosage and administration (2.3) ] between the 9th and 16th weeks of pregnancy showed no increased risk of adverse pregnancy outcomes such as miscarriage, preterm premature rupture of membranes, preterm delivery or pregnancy induced hypertension when compared to placebo. these data cannot definitely establish or exclude the absence of a risk with ascorbic acid (vitamin c) during pregnancy. 8.2 lactation risk summary there are no data on the presence of ascorbic acid (vitamin c) in human milk following intravenous dosing in lactating women. ascorbic acid (vitamin c) is present in human milk after maternal oral intake. maternal oral intake of ascorbic acid (vitamin c) exceeding the u.s. recommended dietary allowances (rda) for lactation does not influence the ascorbic acid (vitamin c) content in breast milk or the estimated daily amount received by breastfed infants. there are no data on the effect of ascorbic acid (vitamin c) on milk production or the breastfed infant. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ascor and any potential adverse effects on the breastfed child from ascor or from the underlying maternal condition. follow the u.s. recommended dietary allowances (rda) for lactating women when considering use of ascor for treatment of scurvy [see dosage and administration (2.3) ]. 8.4 pediatric use ascor is indicated for the short term (up to 1 week) treatment of scurvy in pediatric patients age 5 months and older for whom oral administration is not possible, insufficient or contraindicated. the safety profile of ascorbic acid in pediatric patients is similar to adults; however, pediatric patients less than 2 years of age may be at higher risk of oxalate nephropathy following ascorbic acid administration due to age-related decreased glomerular filtration [ see warnings and precautions (5.1 )]. ascor is not indicated for use in pediatric patients less than 5 months of age. 8.5 geriatric use glomerular filtration rate is known to decrease with age and as such may increase risk for oxalate nephropathy following ascorbic acid administration in elderly population [ see warnings and precautions (5.1 ) ]. 8.6 renal impairment ascor should be used with caution in scorbutic patients with a history of or risk of developing renal oxalate stones or evidence of renal impairment or other issues (e.g., patients on dialysis, patients with diabetic nephropathy, and renal transplant recipients). these patients may be at increased risk of developing acute or chronic oxalate nephropathy following high dose ascorbic acid administration [ see warning and precaution (5.1 ].

Egyesült Államok - angol - NLM (National Library of Medicine)

taleos pharma - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), thiamine hydrochloride (unii: m572600e5p) (thiamine ion - unii:4abt0j945j), riboflavin (unii: tlm2976ofr) (riboflavin - unii:tlm2976ofr), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), pyridoxine hydrochloride (unii: 68y4cf58bv) (pyridoxine - unii:kv2jz1bi6z), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), calcium pantothenate (unii: - ascorbic acid 100 mg - this product is contraindicated in patients with a known hypersensitivity to any of the ingredients.

Egyesült Államok - angol - NLM (National Library of Medicine)

professional complementary health formulas - ascorbic acid 9x, 12x, 30x, 60x - for the temporary relief of occasional headache, itching, fatigue, runny nose, sniffling, wheezing, or congestion due to sensitivity to phenolic compounds found in foods or other products.* *claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Kanada - angol - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - ascorbic acid; sodium ascorbate - tablet - 100mg; 168.75mg - ascorbic acid 100mg; sodium ascorbate 168.75mg - vitamin c

Kanada - angol - Health Canada

stanley pharmaceuticals, a division of vita health products inc. - ascorbic acid; sodium ascorbate - tablet - 50mg; 56.2mg - ascorbic acid 50mg; sodium ascorbate 56.2mg - vitamin c

Kanada - angol - Health Canada

bionatal drug co - ascorbic acid - tablet - 1g - ascorbic acid 1g - vitamin c

Kanada - angol - Health Canada

bionatal drug co - ascorbic acid - tablet - 500mg - ascorbic acid 500mg - vitamin c

Kanada - angol - Health Canada

bionatal drug co - ascorbic acid - tablet - 250mg - ascorbic acid 250mg - vitamin c

Kanada - angol - Health Canada

bionatal drug co - ascorbic acid - tablet - 100mg - ascorbic acid 100mg - vitamin c